Abstract: Pancreatic cancer is considered one of the most lethal cancers being the fourth leading cause of cancer deaths in adults in the United States because of the lack of early signs and symptoms and the lack of early detection. Pancreatic ductal adenocarcinoma (PDAC) is the most common histological type among pancreatic cancers, representing 80%-90% of all solid tumors of the pancreas. The majority of PDAC develops from three precursor lesions: pancreatic intraepithelial neoplasia, intraductual papillary mucinous neoplasm and mucinous cystic neoplasm.
Introduction
Although pancreatic cancer is not typically described as one of the most common human cancers, the incidence appears to be on the rise as the age of the U.S. population increases. Because of the absence of early signs and symptoms and the lack of early detection, this disease has become one of the most lethal cancers being the fourth leading cause of cancer deaths in adults in the United States. For 2016, it is estimated that 53,070 new pancreatic cancer cases will be diagnosed, and that 41,780 people will die from this cancer (SEER) [1] . Despite decades of efforts, the overall 5-year survival rate has remained at around 7%. The dismal prognosis can mainly be attributed to late stage disease at diagnosis as well as inherent tumor cell resistance to standard chemotherapy [2, 3] . Only 9% of pancreatic cancer is diagnosed at the localized stage, whereas the majority of cases present with regional lymph node spread (29%) or with distant metastatic disease to other organs (52%). The 5-year survival for localized versus metastatic disease is 25.8% and 2.3%, respectively.
Pathogenesis of pancreatic cancer: from benign to malignant
The exocrine (including acini and ducts) and the endocrine (islets of Langerhans) tissues are two major components of the pancreas. In normal pancreas, the two components are arranged in lobular configurations separated by thin connective tissue septa ( Figure 1A ). Pancreatic ductal adenocarcinoma (PDAC) is the most common histological type among pancreatic cancers, representing 80%-90% of all solid tumors of the pancreas. Microscopically, it is characterized by malignant cells arranged in a glandular architecture, clusters or single cells surrounded by abundant desmoplastic stroma ( Figure 2A ). The majority of PDACs infiltrate into and/or grow along nerves ( Figure 2B ) [4] . Lymphatic and vascular invasion is also frequently seen in PDACs [5] . PDAC can be further categorized by histologic grade into well, moderately or poorly differentiated groups according to cytological features ( Figure 2A-C) ; this grading system has been shown to correlate well with prognosis [6] . Other types of pancreatic solid neoplasms, such as pancreatic endocrine tumor, acinar cell carcinoma and pancreatoblastoma are less common and less rapidly fatal than PDAC.
Morphologic and molecular genetic analyses show PDAC most frequently associated with pancreatic intraepithelial neoplasia (PanIN), the most common preneoplastic lesion [7] . PanINs are noninvasive microscopic epithelial neoplasms, located often in the smaller pancreatic ducts, characterized by cytological and architectural atypia.
PanIN lesions are subclassified into three grades: PanIN-1, PanIN-2 and PanIN-3, in which PanIN-3 has the highest degree of architecture and cytologic atypia ( Figure 1B) . The epithelium in PanIN-1 has minimal architecture and cytologic atypia, which is frequently seen in nonneoplastic pancreatic parenchyma and the risk of progression to PDAC is very low. The epithelium in PanIN-2 often is papillary and shows moderate architecture and cytologic atypia [5, 8] . In 1998, Brat and collaborators and Brockie and collaborators reported cases in which patients with PanIN-3 later developed an invasive pancreatic cancer [9, 10] .
Diagnosis
Although histologic tissue evaluation remains the gold standard for diagnosis and endoscopic ultrasoundguided fine needle aspiration (EUS-FNA) is widely used to obtain diagnostic material, there are various imaging technologies used to evaluate pancreatic lesions, such as ultrasonography, computed tomography, magnetic resonance imaging, and endoscopic ultrasonography (EUS). However, because of the high accuracy rates for diagnosing pancreatic cancer compared with other imagingguided approaches, EUS-FNA has become the preferred modality for obtaining pathologic confirmation. Currently, the EUS-FNA biopsy is widely used to obtain diagnostic material allowing a pathologic diagnosis with high sensitivity and specificity for pancreatic solid tumors [11] . Studies over the last decade have reported a range in sensitivity from 60% to 100% for the diagnosis of PDAC by EUS-FNA. Many factors can affect the diagnostic yield of EUS-FNA, including the experience of an endoscopist and a cytologist, the availability of on-site cytology and the inherent limitations of the procedure to identify cytomorphological features characteristic of well-differentiated cancer, in particular in the setting of chronic pancreatitis. Sensitivity can also be compromised by technical factors, such as sampling errors, insufficient cellularity and the presence of fibrosis or blood.
In addition, it is difficult to distinguish a benign/nonneoplastic mass forming lesions (e.g., chronic pancreatitis, autoimmune pancreatitis) from malignant lesions solely based on radiographic appearance [12] . Chronic and autoimmune pancreatitis can mimic PDACs on imaging analysis. Patients with autoimmune pancreatitis, especially, can exhibit similar clinical presentations as those seen in the patients with PDAC, such as obstructive jaundice, abdominal pain and weight loss [13] . Because of the overlapping clinical and imaging features between these entities, patients are at high risk for an unnecessary surgical resection [14] .
Because of the lack of a more sensitive and specific biomarker combined with imaging testing, molecular technology has been used to identify biomarkers that have the potential to detect disease at an early stage, as well as predict disease progression, accurately monitor disease and contribute to better treatment strategies. Currently, a large number of studies have shown the importance of microRNA (miRNA) profiling in various human diseases, including cancer.
miRNAs are noncoding RNA molecules of approximately 22 nucleotides in length. They are very stable and can easily be recovered from cell lines, fresh tissue, formalin-fixed paraffin embedded (FFPE) tissue, plasma, serum, urine, stool and other fluids [15, 16] . miRNAs have an important role in biological processes, such as apoptosis, metabolism, cell growth and differentiation, and they regulate gene expression at the posttranscription level [17] . The deregulation of miRNAs can be a result of gene mutations, epigenetic modifications or deficiency in the miRNA processing pathway [17] , and it can result in the development of human diseases, including cancer.
In cancer, miRNAs can be classified as either oncogenic (or oncomirs) or tumor suppressor according to their function in the carcinogenic process. Oncogene miRNAs stimulate proliferation, angiogenesis and invasion by inhibiting tumor suppressor genes or other genes involved in cell differentiation and apoptosis, and tumor suppressor miRNAs prevent carcinogenesis by negatively inhibiting oncogene or other genes that control cell differentiation and apoptosis. Therefore, the deregulation of miRNA expression (overexpression or underexpression) in cancer leads to the inappropriate expression of its target genes and, consequently, results in initiation, progression and/or invasion of the disease, as well as patient response to chemotherapy (resistance or sensitization) [18] [19] [20] [21] .
For this reason, miRNAs have been considered potential biomarkers of human malignancies that could potentially contribute to an early diagnosis, predict disease progression, accurately monitor disease, contribute to better treatment strategies and reduce mortality by improving disease management. In this study, we describe not only the importance of miRNA expression in pancreatic diseases but also our experience with the assessment of miRNA profiling in benign and malignant pancreatic diseases.
miRNA and pancreatic diseases: diagnosis, prognosis and therapeutic targets
Because miRNAs are very stable molecules, high quality and high yield can be obtained from FFPE tissues as well as from clinical specimens with limited tissue yield (such as FNAs). Moreover, miRNAs can be obtained from less invasive procedures, such as peripheral blood, urine, stool and other fluids. In the past years, target RT-PCR and high throughput techniques, such as next-generation sequencing and microarrays, have identified specific miRNA profiles that can precisely differentiate and classify PDAC from normal pancreas and pancreatitis.
For example, in 2013, Xue et al. [22] showed the comparison of miRNA expression in different types of FFPE pancreatic diseases specimens [22] . In this study, miR-148a and miR-217 expression were downregulated in PanIN II-III and PDAC when compared with normal pancreatic parenchyma. However, miR-196 was upregulated in PDAC and its precursor (PanIN II-III). MiR-21 was overexpressed in PDAC, and miR-10b was highly expressed in PanIN II-III. In 2014, Brand et al. [23] developed and validated a miRNA panel that consisted of miR-24, miR-130b, miR135b, miR-148a and miR-196 to better characterize FFPE and EUS-FNA samples. According to these investigators, the detection of PDAC increased from 78.8% by cytology to 90.8% when combined with miRNA analysis. This panel also accurately identified 22 PDAC cases among 39 that were initially classified as benign.
In addition to the screening of FFPE and EUS-FNA specimens, many studies have compared miRNAs expression in blood, stool and cyst fluid of patients with PDAC and healthy controls. In 2009, Wang et al. [24] demonstrated that miR-21, miR-210, miR-155 and miR-196a were upregulated in plasma of patients with PDAC when compared to healthy controls. Recently, two sets of miRNAs were identified to accurately discriminate PDAC patients over the control: (set 1) miR-20a, miR-21, miR-24, miR-25, miR-99a, miR-185 and miR-191; and (set 2) miR-10b, miR-155, miR-106b, miR-30c and miR-212 [25, 26] , respectively. In fecal samples, expression levels of miR-181b and miR-210 were significantly higher in patients with PDAC compared with the normal group [27] . In 2014, Yang et al. [28] evaluated the expression of five miRNAs already shown to be overexpressed in PDAC patients. These investigators revealed that miR-21 and miR-155 were overexpressed in PDAC, and miR-216 was downregulated in all PDAC stool specimens when compared with the normal group. In cyst fluid samples, miR-21 and miR-221 were significantly over-expressed in malignant cysts when compared with benign or premalignant [29] . Other miRNAs have been shown to be upregulated or downregulated in plasma, serum, stool and fluids of patients with pancreatic cancer [30, 31] . Because these findings are consistent with those reported in pancreatic tissue, the less invasive procedures could be used for early diagnosis especially in patients at high risk to develop PDAC.
Because the deregulation of miRNA expression (overexpression or underexpression) influence the expression of target genes by increasing or decreasing their expression, miRNAs can be used not only as a prognostic marker but also as potential therapeutic targets. Although many miRNAs are known to be deregulated in PDAC, not all of them have prognostic effect. High expression of miR-21, miR-196a and miR-10b is associated with worst overall survival; low expression of miR-148a and miR-217 is associated with poor overall survival. However, high expression of miR-34a is associated with better survival, as well as low expression of miR-21 [32] [33] [34] .
Therapeutic applications for miRNAs consist of two strategies: (1) miRNA replacement therapy against loss of function or (2) anti-miRNA therapy against gain of function [20, 31, 35] . The replacement therapy has the potential to replace malfunctioning tumor suppressor miRNAs and overcome carcinogenesis by reestablishing their normal levels. miRNAs Let-7, miR-34a, miR-96, miR-375 and the miR-200 family are the most promising candidates as tumor-suppressive miRNAs [31, 35] . When downregulated, miRNA Let-7 is responsible for renewal and metastasis of pancreatic cancer cells. In gemcitabine-resistant pancreatic cancer cells, the restoration of Let-7 expression promotes inhibition of cellular proliferation, restores epithelial phenotype and renders the tumor cells sensitive to gemcitabine [36] . MiR-34 is involved in cell growth and invasion, and its restoration reduces tumor initiation by inhibiting many oncogenic pathways [37] .
The anti-miRNA therapy has the potential to inhibit overexpressed miRNA, and it can be performed using two main techniques: (1) antisense oligonucleotides (ASOs) and (2) antagomiRs. MiR-21, miR-155, miR-196a, miR-210 and miR-221 family are the most promising candidates as oncogenics miRNAs [35] . ASOs are short molecules that bind to other nucleic acids by Watson-Crick base pairing and block upregulated oncogenic miRNA disturbing their related pathways [38] . AntagomiRs are chemically modified ASOs that degrade the endogenous miRNA in a configuration that is unable to be processed by RISC [35] . For miR-21 and miR-122, ASOs increase the levels of their targets (PTEN, BCL2, RECK and CDKN1B), reduce proliferation and increase apoptosis of pancreatic cancer cells. In addition, they sensitize PDAC cells to gemcitabine [20, 35, 39] .
Currently, there are published preclinical data but no clinical trials on the use of miRNAs in PDAC patients [32] . However, a few clinical trials have evaluated the safety, pharmacokinetics and pharmacodynamics of miR-34 and miR-122 in patients with liver carcinoma. There are also published preclinical data in other diseases using miRNAs, such as glioblastoma, renal fibrosis, atherosclerosis, primary liver cancer or solid cancer with liver involvement, hematological malignancies, peripheral artery disease and myocardial infarction [40] . A synthetic miRNA mimic targeting miR-34 was the first to enter a phase I clinical trial for the treatment of patients with primary liver cancer, advanced solid tumors and hematological malignancies. However, because of a serious immune adverse response, the clinical trial was closed. The miR-122 inhibitor was the first miRNA-targeted therapy that was successful in a phase II clinical trial to combat HCV infection [41] . Because miR-122 binds to two target sites of the HCV genome promoting its propagation, Janssen and collaborators designed an ASO (known as miravirsen) that binds to the mature miR-122 resulting in its functional inhibition. The authors showed that patients with chronic HCV genotype 1 infection treated with miravirsen had prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance.
miRNA and pancreatic diseases: the Dartmouth-Hitchcock Medical Center experience
Many miRNAs are not only shown to be overexpressed or underexpressed in various cancers but also shown to have a distinct expression profile in certain cancer tissues when compared with normal adjacent tissues. There are only a few studies showing miRNA expression profiles along the development and progression of cancer.
In pancreatic diseases, the overexpressed microRNAs involved in increased proliferation, invasion and chemoresistance are miR-155, miR-106a, miR-27a, miR-221/222, miR-224, miR-486, miR-194, miR-200b, miR-200c, miR-429, miR-10a, miR-10b, miR-367, miR-196a, miR-196b, miR-210, miR-375, miR-21 and miR-301a. In addition, the underexpressed miRNAs involved in inhibitory effects on cell proliferation, invasion and metastasis are miR-34a, miR-34b, At the Dartmouth-Hitchcock Medical Center (DHMC), we have designed a panel that consists of miRNAs that are not only overexpressed or underexpression but also differentially expressed at the various stages of the disease, allowing clinicians to distinguish pancreatic cancer from benign pancreatic diseases.
The DHMC miRNA panel is a quantitative real-time reverse-transcriptase PCR assay (qRT-PCR) that consists of five miRNAs (miR-10b, miR-21, miR-196a, miR-217 and miR-148a) and an internal control (RNUB6). This panel was designed and validated with the intent to be incorporated into the routine clinical testing. Table 1 not only summarizes the role and biological function of each miRNA present in this panel but also describes their clinical relevance [16, 33, 34, 42, 43] . miRNA is obtained using the miRNeasy FFPE Kit (Qiagen, Hilden, Germany), and it requires four to six FFPE (formalin-fixed, paraffin-embedded) unstained slides of 5 μm each. Fifty nanograms of RNA is required for cDNA conversion using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR reactions are performed on the 7500 Fast Real-Time PCR System (Applied Biosystems) using TaqMan MicroRNA Assays (Applied Biosystems, Foster City, CA, USA). Expression level and relative expression are obtained by using the formula log 2 (2 −ΔCq ) or log 2 (2 −ΔΔCq ), respectively [22] . The study published Red arrows represent overexpression, and green arrows represent underexpression.
by Xue et al. [22] showed that miRNA analysis can be used to discriminate benign pancreatic lesions from PDAC. In PanIN II-III and PDAC, miR-148a and miR-217 expression levels were downregulated when compared with normal pancreatic parenchyma, and miR-196 was upregulated in PDAC and its precursor (PanIN II-III). MiR-21 was overexpressed in PDAC, and miR-10b was highly expressed in PanIN II-III. In 2010, we performed two studies that also showed that miRNA analysis can be used to discriminate benign pancreatic lesions from PDAC. Hanoun and collaborators [44] reported that hypermethylation of the DNA region encoding miR-148a was responsible for its repression not only in PDAC samples but also in PanIN lesions. Szafranska and collaborators [45] demonstrated lack of miR-196a production in PanIN-1b, which is known to have a low risk for progressing to PDAC. In the intermediate type of pancreatic early lesions (PanIN-2), 25% were positive for miR-196a. However, the miR196a level in PDAC and PanIN-3 lesions was detected above the background level. This study showed that miR-196a production in FNA samples can correlate to advanced high-or intermediaterisk early lesion.
In 2016, a patient was seen at DHMC with a pancreatic mass that appeared invading the portal vein and showed peripancreatic lymphadenopathy. Although the clinical findings were highly concerning for primary pancreatic adenocarcinoma, no evidence of malignancy was identified on the fine needle aspirates. miRNA analysis was performed, and the expression pattern was incompatible with published data of miRNA in pancreatic cancer, thus excluding the diagnosis of malignancy on EUS-FNA as the patient was found to have an autoimmune pancreatitis. On the occasion that an FNA cytology specimen is equivocal or inadequate, we have the ability to run this panel for miRNA markers. The turnaround time for such an assay is two to three working days at a cost of approximately $200 USD to the laboratory (includes FFPE tissue sectioning, RNA extraction, Taqman assays and analysis).
In 2016, we performed a study at DHMC in 19 PDAC patients with and without metastasis (lung, liver, abdominal wall/peritoneum and bone). The expression patterns of miR-10b, miR-21, miR-148a, miR-196a and miR-217 were not predictive of distant metastasis, but both groups showed molecular profile consistent with those reported in PDAC patients (overexpression of miR-21 and downregulated of miR-217). Targeted next-generation sequencing for a panel of 50 genes was performed concurrently with miRNA analysis, and point mutations in the following oncogenes KRAS, TP53
and SMAD4 were identified in six patient samples (two without and four with metastasis).
Conclusions
Many studies have shown the importance of miRNAs in a wide range of biological process, including cell cycle control, cell differentiation, invasion, apoptosis and others. We and others have shown that that the deregulation of miRNA expression plays an important role in the development and progression of pancreatic diseases by disturbing multiple cellular processes, such as cell proliferation, apoptosis, survival, invasion, metastasis and chemotherapeutic resistance. The investigation of the relationship between miRNA and pancreatic diseases allowed for a better understanding of the molecular mechanisms of these diseases. In addition, it also contributed to the identification of a miRNA profile specific to each pancreatic disease type. Our previous work has shown that miRNAs are stable molecules that can be obtained from small FNA specimens with high efficiency. We also showed that miRNA expression profiles can differentiate between various pancreatic lesions including pancreatitis and PDAC. miRNAs are novel biomarkers of pancreatic diseases that can contribute to the overall improvement in patient management.
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